{"id":742131,"date":"2011-04-05T08:30:00","date_gmt":"2011-04-05T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"merck-to-acquire-inspire-pharmaceuticals-inc","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/","title":{"rendered":"Merck to Acquire Inspire Pharmaceuticals, Inc."},"content":{"rendered":"<p class=\"bwalignc\">       Expands and positions ophthalmology portfolio for future growth     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada, and<br \/>\n      Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that they<br \/>\n      have entered into a definitive agreement under which Merck will acquire<br \/>\n      Inspire, a specialty pharmaceutical company focused on developing and<br \/>\n      commercializing ophthalmic products.\n    <\/p>\n<p>\n      <b>\u201cMerck continues to build upon its long-term commitment to improving<br \/>\n      therapeutic options for the treatment of eye diseases\u201d<\/b>\n    <\/p>\n<p>\n      Under the terms of the agreement, Merck, through a subsidiary, will<br \/>\n      commence a tender offer for all outstanding common stock of Inspire at a<br \/>\n      price of $5.00 per share in cash, a 26 percent premium to the closing<br \/>\n      price of Inspire\u2019s common stock on April 4, 2011. The transaction has a<br \/>\n      total cash value of approximately $430 million. The transaction has been<br \/>\n      unanimously approved by the boards of directors of both companies and<br \/>\n      Inspire\u2019s board recommended that the company&#8217;s shareholders tender their<br \/>\n      shares pursuant to the tender offer. In addition, Warburg Pincus Private<br \/>\n      Equity IX, L.P., which owns approximately 28 percent of the outstanding<br \/>\n      shares of Inspire, has agreed to tender all of its shares into the offer.\n    <\/p>\n<p>\n      &#8220;Merck continues to build upon its long-term commitment to improving<br \/>\n      therapeutic options for the treatment of eye diseases,&#8221; said Beverly<br \/>\n      Lybrand, senior vice president and general manager, neuroscience and<br \/>\n      ophthalmology, Merck. &#8220;This acquisition combines the talented<br \/>\n      commercialization organization at Inspire with the excellent team<br \/>\n      already in place at Merck thereby strengthening our ophthalmology<br \/>\n      business and positioning us for future growth with an expanded<br \/>\n      portfolio. This deal helps address the needs of patients and customers<br \/>\n      in ophthalmology and creates value for both companies.&#8221;\n    <\/p>\n<p>\n      In March, 2011, Merck announced that the New Drug Application (NDA) for<br \/>\n      SAFLUTAN<sup>\u00ae<\/sup> (tafluprost), an investigational preservative-free<br \/>\n      prostaglandin analogue ophthalmic solution, had been accepted for<br \/>\n      standard review by the U.S. Food and Drug Administration (FDA). SAFLUTAN<br \/>\n      is the proposed trade name for tafluprost in the United States.\n    <\/p>\n<p>\n      \u201cAs one of the world\u2019s leading healthcare companies, Merck is the ideal<br \/>\n      partner to enhance the long-term potential of Inspire\u2019s portfolio of<br \/>\n      ophthalmic assets. We are delighted that Merck recognized the strength<br \/>\n      of an integrated platform leveraging the growing AZASITE<sup>\u00ae<\/sup><br \/>\n      (azithromycin ophthalmic solution) 1% product opportunity and the strong<br \/>\n      relationships within the ophthalmic community cultivated by our high<br \/>\n      quality, specialty eye care sales force in the U.S.,\u201d said Adrian Adams,<br \/>\n      president and CEO of Inspire. \u201cBased upon an extensive analysis of<br \/>\n      various strategic options, as I have outlined since we announced the<br \/>\n      results of the TIGER-2 Phase 3 clinical trial, we believe this<br \/>\n      combination provides a compelling and timely opportunity for our<br \/>\n      shareholders to realize the value of their investment in Inspire.\u201d\n    <\/p>\n<p>\n      The closing of the tender offer will be subject to certain conditions,<br \/>\n      including the tender of a number of Inspire shares that, together with<br \/>\n      shares owned by Merck, represent at least a majority of the total number<br \/>\n      of Inspire&#8217;s outstanding shares (assuming the exercise of all options<br \/>\n      and vesting of restricted stock units), the expiration of the waiting<br \/>\n      period under the Hart-Scott-Rodino Antitrust Improvements Act and other<br \/>\n      customary conditions. Upon the completion of the tender offer, Merck<br \/>\n      will acquire all remaining shares through a second-step merger.\n    <\/p>\n<p>\n      <b>About AZASITE<\/b>\n    <\/p>\n<p>\n      <b>Indication:<\/b> AZASITE<sup>\u00ae<\/sup> (azithromycin ophthalmic<br \/>\n      solution) 1% is indicated for the treatment of bacterial conjunctivitis<br \/>\n      in patients one year and older caused by the following organisms: CDC<br \/>\n      coryneform group G*, <i>Haemophilus influenzae<\/i>, <i>Staphylococcus<br \/>\n      aureus<\/i>, <i>Streptococcus mitis<\/i> group, and <i>Streptococcus<br \/>\n      pneumoniae<\/i>.\n    <\/p>\n<p>\n      <b>Important Selected Safety Information:<\/b> AZASITE should not be<br \/>\n      administered systemically, injected subconjunctivally, or introduced<br \/>\n      directly into the anterior chamber of the eye. In patients receiving<br \/>\n      systemically administered azithromycin, serious allergic reactions,<br \/>\n      including angioedema, anaphylaxis, Stevens Johnson Syndrome and toxic<br \/>\n      epidermal necrolysis have been reported rarely. Although rare,<br \/>\n      fatalities have been reported.\n    <\/p>\n<p>\n      As with other anti-infectives, prolonged use may result in overgrowth of<br \/>\n      non-susceptible organisms, including fungi. If super-infection occurs,<br \/>\n      discontinue use and institute alternative therapy. Patients should not<br \/>\n      wear contact lenses if they have signs or symptoms of bacterial<br \/>\n      conjunctivitis.\n    <\/p>\n<p>\n      Azithromycin should be used during pregnancy only if clearly needed.\n    <\/p>\n<p>\n      The most frequently reported ocular adverse event reported in clinical<br \/>\n      trials was eye irritation which occurred in 1-2 percent of patients.<br \/>\n      Other adverse events reported in &lt;1 percent of patients included: ocular<br \/>\n      reactions (blurred vision, burning, stinging and irritation upon<br \/>\n      instillation, contact dermatitis, corneal erosion, dry eye, eye pain,<br \/>\n      itching, ocular discharge, punctate keratitis, visual acuity reduction)<br \/>\n      and non-ocular reactions (dysgeusia, facial swelling, hives, nasal<br \/>\n      congestion, periocular swelling, rash, sinusitis, urticaria).\n    <\/p>\n<p>\n      *Efficacy for this organism was studied in fewer than 10 infections.\n    <\/p>\n<p>\n      <b>About Inspire<\/b>\n    <\/p>\n<p>\n      Inspire is a specialty pharmaceutical company focused on developing and<br \/>\n      commercializing ophthalmic products. Inspire&#8217;s specialty eye care sales<br \/>\n      force generates revenue from the promotion of AZASITE<sup>\u00ae<\/sup><br \/>\n      (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis.<br \/>\n      Inspire receives royalties based on net sales of RESTASIS<sup>\u00ae <\/sup>(cyclosporine<br \/>\n      ophthalmic emulsion) 0.05% and DIQUAS<sup>\u2122<\/sup> Ophthalmic Solution 3%<br \/>\n      (diquafosol tetrasodium) in Japan. For more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.inspirepharm.com&amp;esheet=50284404&amp;lan=en-US&amp;anchor=www.inspirepharm.com&amp;index=1&amp;md5=01d10faa68d68f6d57538efaf9be9b88\">www.inspirepharm.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com%2F&amp;esheet=50284404&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=2&amp;md5=796795024f81e81ce7937cef04e40710\">www.merck.com<\/a>.\n    <\/p>\n<p>\n      <b>Inspire Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. The forward-looking statements<br \/>\n      in this news release relating to management&#8217;s expectations and beliefs<br \/>\n      are based on preliminary information and management assumptions.<br \/>\n      Specifically, no assurances can be made that the holders of at least a<br \/>\n      majority of the outstanding shares of Inspire\u2019s common stock will tender<br \/>\n      their shares pursuant to the tender offer or that the other conditions<br \/>\n      of the tender offer will be met. Furthermore, no assurances can be made<br \/>\n      with respect to the strength of Inspire\u2019s integrated platform growing<br \/>\n      the AZASITE product opportunity.\n    <\/p>\n<p>\n      Such forward-looking statements are subject to a wide range of risks and<br \/>\n      uncertainties that could cause results to differ in material respects,<br \/>\n      including those relating to product development, revenue, expense and<br \/>\n      earnings expectations, the introduction of a generic form of epinastine,<br \/>\n      intellectual property rights, competitive products, results and timing<br \/>\n      of clinical trials, success of marketing efforts, the need for<br \/>\n      additional research and testing, delays in manufacturing, funding, and<br \/>\n      the timing and content of decisions made by regulatory authorities,<br \/>\n      including the U.S. Food and Drug Administration. Further information<br \/>\n      regarding factors that could affect Inspire&#8217;s results is included in<br \/>\n      Inspire&#8217;s filings with the SEC. Inspire undertakes no obligation to<br \/>\n      publicly release the results of any revisions to these forward-looking<br \/>\n      statements that may be made to reflect events or circumstances after the<br \/>\n      date hereof.\n    <\/p>\n<p>\n      <b>Merck Forward Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. Such statements may include,<br \/>\n      but are not limited to, statements about the benefits of the merger<br \/>\n      between Merck and Schering-Plough, including future financial and<br \/>\n      operating results, the combined company\u2019s plans, objectives,<br \/>\n      expectations and intentions and other statements that are not historical<br \/>\n      facts. Such statements are based upon the current beliefs and<br \/>\n      expectations of Merck\u2019s management and are subject to significant risks<br \/>\n      and uncertainties. Actual results may differ from those set forth in the<br \/>\n      forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      possibility that the expected synergies from the merger of Merck and<br \/>\n      Schering-Plough will not be realized, or will not be realized within the<br \/>\n      expected time period; the impact of pharmaceutical industry regulation<br \/>\n      and health care legislation; the risk that the businesses will not be<br \/>\n      integrated successfully; disruption from the merger making it more<br \/>\n      difficult to maintain business and operational relationships; Merck\u2019s<br \/>\n      ability to accurately predict future market conditions; dependence on<br \/>\n      the effectiveness of Merck\u2019s patents and other protections for<br \/>\n      innovative products; the risk of new and changing regulation and health<br \/>\n      policies in the United States and internationally and the exposure to<br \/>\n      litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50284404&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=3&amp;md5=8a65e19cb522aff12cf06a87d6e7193b\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Important Information about the Tender Offer<\/b>\n    <\/p>\n<p>\n      The description contained in this press release is neither an offer to<br \/>\n      purchase nor a solicitation of an offer to sell securities. The planned<br \/>\n      tender offer described in this press release has not commenced. At the<br \/>\n      time the planned tender offer is commenced, a tender offer statement on<br \/>\n      Schedule TO will be filed by Merck with the SEC, and Inspire will file a<br \/>\n      solicitation\/recommendation statement on Schedule 14D-9, with respect to<br \/>\n      the planned tender offer. The tender offer statement (including an offer<br \/>\n      to purchase, a related letter of transmittal and other tender offer<br \/>\n      documents) and the solicitation\/recommendation statement will contain<br \/>\n      important information that should be re ad carefully before making any<br \/>\n      decision to tender securities in the planned tender offer. Those<br \/>\n      materials will be made available to Inspire\u2019s stockholders at no expense<br \/>\n      to them. In addition, all of those materials (and all other tender offer<br \/>\n      documents filed with the SEC) will be made available at no charge on the<br \/>\n      SEC\u2019s website at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50284404&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=6c8b6c884221179b22bccaef8144525b\">www.sec.gov<\/a>.\n    <\/p>\n<p>\n      <b>SAFLUTAN<\/b><sup><b>\u00ae<\/b><\/sup><b> is a registered trademark of<br \/>\n      Merck, Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc.<\/b><br \/>\n      <b>All other brands are trademarks of their respective owners and are<br \/>\n      not trademarks of Merck &amp; Co., Inc., Whitehouse Station, N.J., USA<\/b>\n    <\/p>\n<p>\n      Photos\/Multimedia Gallery Available: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6672219%26lang%3Den&amp;esheet=50284404&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6672219%26lang%3Den&amp;index=5&amp;md5=4f0227ee00651d57e2261223e0008f64\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=6672219&amp;lang=en<\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell<br \/>908-423-3046<br \/>Investor:<br \/>Carol        Ferguson or Joe Romanelli<br \/>908-423-5088<br \/>or<br \/>Inspire        Pharmaceuticals, Inc.<br \/>Media:<br \/>Cara Amoroso<br \/>919-287-1266<br \/>or<br \/>Investor:<br \/>Jenny        Kobin<br \/>919-287-1219     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Expands and positions ophthalmology portfolio for future growth Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. \u201cMerck continues to build upon its long-term commitment to improving therapeutic options for the treatment of eye diseases\u201d Under the terms of the agreement, Merck, through a subsidiary, will commence a tender offer for all outstanding common stock of Inspire at a price of $5.00 per share in cash, a 26 percent premium to the closing price of Inspire\u2019s common stock on April 4, 2011. The transaction has a total cash value of approximately $430 million. The transaction has been unanimously approved by the boards of directors of both companies and Inspire\u2019s board recommended that the company&#8217;s shareholders<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742131","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck to Acquire Inspire Pharmaceuticals, Inc. - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck to Acquire Inspire Pharmaceuticals, Inc. - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Expands and positions ophthalmology portfolio for future growth Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. \u201cMerck continues to build upon its long-term commitment to improving therapeutic options for the treatment of eye diseases\u201d Under the terms of the agreement, Merck, through a subsidiary, will commence a tender offer for all outstanding common stock of Inspire at a price of $5.00 per share in cash, a 26 percent premium to the closing price of Inspire\u2019s common stock on April 4, 2011. The transaction has a total cash value of approximately $430 million. The transaction has been unanimously approved by the boards of directors of both companies and Inspire\u2019s board recommended that the company&#039;s shareholders\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/\",\"name\":\"Merck to Acquire Inspire Pharmaceuticals, Inc. - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2011-04-05T08:30:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-to-acquire-inspire-pharmaceuticals-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck to Acquire Inspire Pharmaceuticals, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck to Acquire Inspire Pharmaceuticals, Inc. - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/","og_locale":"en_US","og_type":"article","og_title":"Merck to Acquire Inspire Pharmaceuticals, Inc. - Merck.com","og_description":"Expands and positions ophthalmology portfolio for future growth Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced that they have entered into a definitive agreement under which Merck will acquire Inspire, a specialty pharmaceutical company focused on developing and commercializing ophthalmic products. \u201cMerck continues to build upon its long-term commitment to improving therapeutic options for the treatment of eye diseases\u201d Under the terms of the agreement, Merck, through a subsidiary, will commence a tender offer for all outstanding common stock of Inspire at a price of $5.00 per share in cash, a 26 percent premium to the closing price of Inspire\u2019s common stock on April 4, 2011. The transaction has a total cash value of approximately $430 million. The transaction has been unanimously approved by the boards of directors of both companies and Inspire\u2019s board recommended that the company's shareholders","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/","name":"Merck to Acquire Inspire Pharmaceuticals, Inc. - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2011-04-05T08:30:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120521005623r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-to-acquire-inspire-pharmaceuticals-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck to Acquire Inspire Pharmaceuticals, Inc."}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"bf546110-4140-4105-9b0c-c2a88a98a499","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-to-Acquire-Inspire-Pharmaceuticals-Inc-2011.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742131\/revisions"}],"predecessor-version":[{"id":3679267,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742131\/revisions\/3679267"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742131"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}